Advancing the Treatment Landscape in Polycythemia Vera (PV): Patient-Centered Approaches

A panelist discusses how a 67-year-old male smoker presented with frequent headache and dizziness but had an otherwise unremarkable medical history with no splenomegaly.

A panelist discusses how a patient’s initial presentation and molecular profile guide personalized treatment approaches for polycythemia vera (PV), weighing factors such as symptom burden, risk stratification, and genetic markers to optimize therapeutic outcomes.

A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess polycythemia vera (PV) disease progression and guide initial treatment decisions by providing quantifiable markers for tracking mutation burden, treatment response, and risk stratification that complement traditional clinical parameters.

A panelist discusses how patient-reported outcomes have transformed their ability to deliver more personalized care approaches for patients with polycythemia vera (PV) by providing critical insights into symptom burden, quality-of-life impacts, and treatment effectiveness that might otherwise go unrecognized through standard clinical assessments alone.

A panelist discusses how they prioritize specific clinical and laboratory parameters when assessing response to first-line therapy in patients with polycythemia vera (PV) requiring combined phlebotomy and cytoreductive treatment, focusing on hematocrit control, symptom improvement, phlebotomy frequency reduction, and molecular marker trends as key indicators of therapeutic efficacy.

A panelist discusses how detailed clinical assessments of hematologic parameters, symptom burden, thrombotic risk, and molecular markers inform necessary treatment modifications when initial therapeutic approaches prove inadequate in patients with polycythemia vera (PV).

A panelist discusses how available therapeutic strategies have enhanced their approach to treatment sequencing in patients with polycythemia vera (PV) by providing a broader armamentarium that allows for customized stepwise management based on disease characteristics, risk stratification, treatment response, and evolving symptom burden.

A panelist discusses how recent advancements in molecular diagnostics, targeted therapies, and individualized treatment approaches give them greatest optimism for patients with polycythemia vera (PV) by potentially altering disease trajectory, reducing complications, and significantly improving quality of life and long-term outcomes.